地诺单抗在慢性肾脏病相关性骨质疏松症中的应用：一项叙述性综述。
Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review.
作者信息
Abduelkarem Abduelmula R, Guella Adnane, Hamrouni Amar M, Hassanein Mohammed M, Nasr Ahmed, Rana Owais
机构信息
Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
出版信息
Risk Manag Healthc Policy. 2023 Sep 11;16:1809-1813. doi: 10.2147/RMHP.S426869. eCollection 2023.
Chronic kidney disease (CKD) and hemodialysis (HD) patients have a high incidence of bone disease and increased fracture risk, making effective management of their bone health a clinical challenge. Denosumab, a human monoclonal antibody, has been investigated as a therapeutic option in this patient population. In this review, we summarize the current evidence on the efficacy and safety of denosumab in CKD and HD patients. A comprehensive search of the relevant literature was conducted, including randomized controlled trials, observational studies, and meta-analyses. The findings suggest that denosumab reduces the risk of fractures and improves bone mineral density in all stages of CKD. The results of this review support the use of denosumab as a promising option for managing bone disease in CKD and HD patients.
慢性肾脏病（CKD）患者和接受血液透析（HD）的患者骨病发病率高，骨折风险增加，因此有效管理他们的骨骼健康成为一项临床挑战。地诺单抗，一种人源单克隆抗体，已被作为该患者群体的一种治疗选择进行研究。在本综述中，我们总结了目前关于地诺单抗在CKD和HD患者中疗效和安全性的证据。我们对相关文献进行了全面检索，包括随机对照试验、观察性研究和荟萃分析。研究结果表明，地诺单抗可降低CKD各阶段的骨折风险并提高骨矿物质密度。本综述结果支持将地诺单抗作为管理CKD和HD患者骨病的一种有前景的选择。
Zotero 插件